XYP-217

N/A

Report date: 2025/01/26 17:54:40

Base Information

Drug NameXYP-217

Drug Alias Nameanti-CD20 convertibleCAR-T cell therapy (Xyphos)Anti-CD20 CAR T-Cell Therapy (Xyphos)cCAR-T-Cell Therapy (Xyphos)XYP-217

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD20 modulators

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Non-HodgkinNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesXyphos Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesXyphos Biosciences Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-Hodgkin

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A